CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE CTA APPROVAL FOR CLINICAL STUDY OF BI-1206 IN NHL IN CHINA
Canada
Argentina 
Australia 
Austria 
Brazil 
Germany 
Ireland 
Italy 
Malaysia 
Mexico 
New Zealand 
Poland 
South Africa 
United Kingdom 
United States 
